Actinium Pharmaceuticals Inc (ATNM)

[blukky]

Maxim Group Maintains a Buy Rating on Actinium Pharmaceuticals (ATNM)

Jason Carr-August 14, 2018, 7:55 PM EDTSHARE ON:

In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Actinium Pharmaceuticals (NYSE: ATNM), with a price target of $3. The company’s shares opened today at $0.62.

McCarthy observed:

“Actinium announced that the Data Monitoring Committee (DMC) unanimously voted to recommend the Phase 3 SIERRA trial of Iomab-B to continue as planned. The interim safety look occurred at the 25% enrollment mark. The company will host a conference call Wednesday/tomorrow at 9am ET.”

According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 11.6% and a 42.8% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.

Currently, the analyst consensus on Actinium Pharmaceuticals is a Strong Buy with an average price target of $4.25.